Gabather

Gabather Stock-Based Compensation

Stock-Based Compensation (SBC) of Gabather (GABA.ST) as of Nov 4, 2026.

Stock-Based Compensation

-SEK

Last updated:

Stock-Based Compensation (SBC) of Gabather is 2026 - SEK. Stock-Based Compensation (SBC) of Gabather was 2025 - SEK. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Gabather Stock analysis

What does Gabather do? Gabather AB engages in the research and development of drug candidates for the treatment of diseases affecting the central nervous system. The firm develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The firm mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease. Gabather is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gabather stock

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Gabather since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Gabather historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Gabather

All Key Metrics — Gabather